Neuer Start, neuer Risk!!! (Seite 6)
eröffnet am 14.05.16 01:52:48 von
neuester Beitrag 18.08.22 14:24:11 von
neuester Beitrag 18.08.22 14:24:11 von
Beiträge: 100
ID: 1.231.746
ID: 1.231.746
Aufrufe heute: 1
Gesamt: 12.453
Gesamt: 12.453
Aktive User: 0
ISIN: US72941H5090 · WKN: A3EEZB
2,0600
EUR
0,00 %
0,0000 EUR
Letzter Kurs 18:34:45 Lang & Schwarz
Werte aus der Branche Gesundheitswesen
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 7,0000 | +6.045,74 | |
| 0,8600 | +36,51 | |
| 0,8600 | +17,95 | |
| 1,2900 | +12,17 | |
| 13,970 | +10,43 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,9080 | -14,82 | |
| 3,0100 | -17,31 | |
| 0,6000 | -18,92 | |
| 1,4500 | -21,62 | |
| 3,5800 | -24,79 |
Beitrag zu dieser Diskussion schreiben
Feedback
Cytori Reports Reduction in Fibrosis Parameters in Scar Study
GlobeNewswire•November 20, 2017
SAN DIEGO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using Cytori Cell Therapy™ in a model of fibrotic scar formation. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical proof of concept data package incorporated into the FDA approved United States RELIEF Trial.
The publication describes a study in which Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring. Six months after treatment, wounds that were treated with ADRCs showed reduction in parameters associated with hypertrophic scarring compared to control wounds. Parameters that were improved by treatment included skin hardness, organization, vascularity, and discoloration. Molecular analysis implicated the temporal modulation of Interleukin-6 expression, a key regulator of the inflammatory response, as a potential mediator of the effect.
The paper entitled “Autologous adipose-derived regenerative cell therapy modulates development of hypertrophic scarring in a red Duroc porcine model ” just published in the journal Stem Cell Research and Therapy and is now available online.
The findings from this preclinical study were incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial will assess Cytori Cell Therapy in human patients with substantial thermal burn injury. In addition to assessment of early healing, the RELIEF trial will evaluate several scar-related parameters using approaches similar to those applied in this study.
“Fibrosis is a common factor in both burns and scleroderma.” said Dr. John Fraser, Chief Scientist at Cytori. “This preclinical study is consistent with a number of emerging studies indicating a beneficial effect of Cytori’s ADRC technology in fibrotic disease.”
The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from pain, scarring, skin contracture and reduced range of motion. Hypertrophic scarring is characterized by raised, discolored, itchy and painful scars that are a common fibrotic consequence of deep-partial thickness burn injury.
Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.
About RELIEF
The RELIEF trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft (STSG). Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial will also assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 30 patients in up to 10 U.S. sites with study initiation expected to occur soon.
https://finance.yahoo.com/news/cytori-reports-reduction-fibr…
GlobeNewswire•November 20, 2017
SAN DIEGO, Nov. 20, 2017 (GLOBE NEWSWIRE) -- Cytori Therapeutics, Inc. (CYTX) announced today the publication of preclinical data from a study using Cytori Cell Therapy™ in a model of fibrotic scar formation. This study was performed with support from the Biomedical Advanced Research and Development Authority (BARDA) as a component of the preclinical proof of concept data package incorporated into the FDA approved United States RELIEF Trial.
The publication describes a study in which Adipose Derived Regenerative Cells (ADRCs), the active component of Cytori Cell Therapy™, were injected into deep partial thickness wounds in a porcine model, considered the gold standard preclinical model of hypertrophic scarring. Six months after treatment, wounds that were treated with ADRCs showed reduction in parameters associated with hypertrophic scarring compared to control wounds. Parameters that were improved by treatment included skin hardness, organization, vascularity, and discoloration. Molecular analysis implicated the temporal modulation of Interleukin-6 expression, a key regulator of the inflammatory response, as a potential mediator of the effect.
The paper entitled “Autologous adipose-derived regenerative cell therapy modulates development of hypertrophic scarring in a red Duroc porcine model ” just published in the journal Stem Cell Research and Therapy and is now available online.
The findings from this preclinical study were incorporated into the design of the RELIEF clinical trial of Cytori Cell Therapy™ which is also funded by BARDA. The RELIEF trial will assess Cytori Cell Therapy in human patients with substantial thermal burn injury. In addition to assessment of early healing, the RELIEF trial will evaluate several scar-related parameters using approaches similar to those applied in this study.
“Fibrosis is a common factor in both burns and scleroderma.” said Dr. John Fraser, Chief Scientist at Cytori. “This preclinical study is consistent with a number of emerging studies indicating a beneficial effect of Cytori’s ADRC technology in fibrotic disease.”
The treatment of thermal burns remains a critical unmet medical need. Despite standard of care primarily consisting of dressings, skin grafts and skin substitutes, patients frequently suffer from pain, scarring, skin contracture and reduced range of motion. Hypertrophic scarring is characterized by raised, discolored, itchy and painful scars that are a common fibrotic consequence of deep-partial thickness burn injury.
Autologous cell therapies such as those offered by Cytori have the potential to improve the quality and rate of wound healing and reduce scarring. In a mass casualty event, the Government Accountability Office estimates that as many as 10,000 patients could require thermal burn care. The limited number of specialist surgeons and burn centers in the U.S. creates a public health need for a burn wound therapy that can be quickly and broadly applied by non-specialist medical personnel following such an event. Therefore, autologous Cytori’s Cell Therapy represents a novel medical countermeasure not only to address these challenges but also to promote wound healing and tissue repair and improve casualty care.
About RELIEF
The RELIEF trial will assess safety and feasibility of intravenous delivery of Cytori Cell Therapy™ as an adjunct to usual care in patients with thermal burn injuries covering between 20% and 50% of their body surface area. Subjects will have at least one deep partial or full thickness burn wound that is to be treated with a meshed autologous split thickness skin graft (STSG). Subjects will be randomized (1:2) to receive either usual care alone or usual care supplemented with Cytori Cell Therapy. While primarily focusing on safety and feasibility, the RELIEF trial will also assess a series of parameters related to skin graft healing. The trial is approved to enroll up to 30 patients in up to 10 U.S. sites with study initiation expected to occur soon.
https://finance.yahoo.com/news/cytori-reports-reduction-fibr…
Cytori's generic doxorubicin candidate ATI-0918 matches branded versions in bioequivalence study; shares ahead 4%
Nov. 16, 2017 11:53 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
•Cytori Therapeutics (CYTX +4.3%) is up, albeit of light volume, in response to the results from a pharmacokinetic bioequivalence study comparing its doxorubicin hydrochloride candidate ATI-0918 to Johnson & Johnson (JNJ -0.1%) unit Janssen's CAELYX and Sun Pharma's Lipodox. The data were presented at the American Association of Pharmaceutical Scientists Annual Meeting in San Diego.
•The study confirmed bioequivalence.
•Cytori is actively seeking commercial partners for the asset.
https://seekingalpha.com/news/3312933-cytoris-generic-doxoru…
Nov. 16, 2017 11:53 AM ET|About: Cytori Therapeutics Inc (CYTX)|By: Douglas W. House, SA News Editor
•Cytori Therapeutics (CYTX +4.3%) is up, albeit of light volume, in response to the results from a pharmacokinetic bioequivalence study comparing its doxorubicin hydrochloride candidate ATI-0918 to Johnson & Johnson (JNJ -0.1%) unit Janssen's CAELYX and Sun Pharma's Lipodox. The data were presented at the American Association of Pharmaceutical Scientists Annual Meeting in San Diego.
•The study confirmed bioequivalence.
•Cytori is actively seeking commercial partners for the asset.
https://seekingalpha.com/news/3312933-cytoris-generic-doxoru…
Cytori Therapeutics (CYTX) Says Its STAR Trial Data Accepted for Presentation at Systemic Sclerosis World Congress
November 7, 2017 9:11 AM EST
Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma (SSc) has been accepted for presentation at the 5th Systemic Sclerosis World Congress on February 15-17, 2018 in Bordeaux, France.
The presentation will include a full data analysis, beyond the top-line results previously reported by the company in July and October 2017, specifically:
While there were trends toward greater improvement in the primary endpoint, Cochin Hand Function Score [CHFS], for Habeo compared to placebo at 24 and 48 weeks, for both time points these differences did not achieve statistical significance of p≤0.05.
The pre-specified analysis of 51 subjects with diffuse SSc showed a clinically meaningful treatment benefit at 48 weeks in both the CHFS (improvement of 12.0 points for Habeo compared to 6.6 in the placebo group) and in a secondary endpoint, the Health Assessment Questionnaire Disability Index [HAQ-DI] (improvement of 0.21 points compared with 0.04 in the placebo). These differences approached or achieved statistical significance (p=0.069 and p=0.044, respectively).
Subsequent data analysis of these and other key endpoints in patients with diffuse SSc are also consistent with a treatment effect:
Responder analysis for the HAQ-DI score at 48 weeks, based on published minimal clinical important differences, showed that 63% of patients in the Habeo group had a clinically-important improvement compared with only 26% of patients in the placebo group (p=0.019)
A standardized measure of health-related quality of life, EQ-5D, showed that 50% of patients in the placebo group exhibited clinically-important worsening at 48 weeks compared to only 3% in the Habeo group (p=0.0002).
Patients in the Habeo group, compared to the placebo group, also exhibited a reduced number of new ulcers over the 48 week study period (mean 1.72/patient compared with 3.74/patient in the placebo group; p=0.178), delayed time to first new ulcer (p=0.116), and greater improvement in hand mobility at 48 weeks, as measured by 2nd-4th corner distance of right hand (~5.5 mm increase vs. ~0.6 mm decrease, respectively; p=0.135).
The full data set will be presented at the 5th Systemic Sclerosis World Congress on February 15-17, 2018.
STAR was a randomized, placebo-controlled, double-blind, parallel group, U.S. clinical trial intended to study the safety and efficacy of Habeo Cell Therapy in 88 subjects with hand dysfunction due to scleroderma at 19 U.S. centers. Cytori is currently working with statisticians and study investigators in preparation for publication of these results in a peer-reviewed journal.
https://www.streetinsider.com/Corporate+News/Cytori+Therapeu…
November 7, 2017 9:11 AM EST
Cytori Therapeutics, Inc. (Nasdaq: CYTX) announced today that its U.S. STAR clinical trial assessing the safety and efficacy of Habeo™ Cell Therapy for hand dysfunction due to systemic scleroderma (SSc) has been accepted for presentation at the 5th Systemic Sclerosis World Congress on February 15-17, 2018 in Bordeaux, France.
The presentation will include a full data analysis, beyond the top-line results previously reported by the company in July and October 2017, specifically:
While there were trends toward greater improvement in the primary endpoint, Cochin Hand Function Score [CHFS], for Habeo compared to placebo at 24 and 48 weeks, for both time points these differences did not achieve statistical significance of p≤0.05.
The pre-specified analysis of 51 subjects with diffuse SSc showed a clinically meaningful treatment benefit at 48 weeks in both the CHFS (improvement of 12.0 points for Habeo compared to 6.6 in the placebo group) and in a secondary endpoint, the Health Assessment Questionnaire Disability Index [HAQ-DI] (improvement of 0.21 points compared with 0.04 in the placebo). These differences approached or achieved statistical significance (p=0.069 and p=0.044, respectively).
Subsequent data analysis of these and other key endpoints in patients with diffuse SSc are also consistent with a treatment effect:
Responder analysis for the HAQ-DI score at 48 weeks, based on published minimal clinical important differences, showed that 63% of patients in the Habeo group had a clinically-important improvement compared with only 26% of patients in the placebo group (p=0.019)
A standardized measure of health-related quality of life, EQ-5D, showed that 50% of patients in the placebo group exhibited clinically-important worsening at 48 weeks compared to only 3% in the Habeo group (p=0.0002).
Patients in the Habeo group, compared to the placebo group, also exhibited a reduced number of new ulcers over the 48 week study period (mean 1.72/patient compared with 3.74/patient in the placebo group; p=0.178), delayed time to first new ulcer (p=0.116), and greater improvement in hand mobility at 48 weeks, as measured by 2nd-4th corner distance of right hand (~5.5 mm increase vs. ~0.6 mm decrease, respectively; p=0.135).
The full data set will be presented at the 5th Systemic Sclerosis World Congress on February 15-17, 2018.
STAR was a randomized, placebo-controlled, double-blind, parallel group, U.S. clinical trial intended to study the safety and efficacy of Habeo Cell Therapy in 88 subjects with hand dysfunction due to scleroderma at 19 U.S. centers. Cytori is currently working with statisticians and study investigators in preparation for publication of these results in a peer-reviewed journal.
https://www.streetinsider.com/Corporate+News/Cytori+Therapeu…
This is maybe a little bit old info, but might give you a detail info what happened and what might can happen. Still risky stock and all depends on the outcome of the Europe trials.
Cytori Therapeutics Inc (NASDAQ:CYTX) Could Still Win In Scleroderma. Here's How.
By Chris Sandburg
Posted on July 25, 2017
If you are looking for one of the biggest biotechnology losses of the week so far, look no further than Cytori Therapeutics Inc (NASDAQ:CYTX). The company closed out last week at around $1.10 a share. By market open on Monday, Cytori went for around $0.40 apiece and remained pretty much flat on the open to close out the session at $0.48 a share.
The decline comes on the back of the company putting out data from one of its lead investigations and – as readers might have guessed – the data not hitting press as Cytori or its shareholders might have hoped it would.
Markets are asking the question – is there any value in picking up exposure at current prices or is this an asset (and in turn, a company) to write off for now?
Here is our answer to that question.
The trial was rooted in a drug called Habeo that attempts to use what are called dipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human’s own adipose tissue, to help regenerate healthy tissue in conditions associated with cell degeneration. The company removes these cells from the patient using liposuction, adds them to a liquid suspension and then concentrates them into a substance that can be reintroduced into the body by way of subcutaneous injection.
In this instance, the target indication was scleroderma, which is a rare and chronic connective tissue disease generally classified as an autoimmune rheumatic disorder. It’s characterized by significant hand dysfunction, and this latter characterization played a key role in the trials determinant outcome.
So, specifically, the company injected its Habeo therapy into a total of 88 patients with scleroderma, including 51 patients with a type called diffuse cutaneous and 37 with another type called limited cutaneous scleroderma. These patients were then followed up at 24 and 48 weeks’ post-treatment to see if their scleroderma had improved, using a scale called the Cochin Hand Function Score (CHF score) to judge improvement.
As per the latest data, the drug failed against its primary endpoint (an improvement from baseline based on the above-mentioned CHF score) at both 24 weeks and 48 weeks.
So, not great.
It’s not all bad, however. The company did manage to show some degree of improvement (a statistically significant one at that) in one of the subgroups of patients – the patients with the diffuse cutaneous form of the disease.
This part is important: if this improvement was recognized after the trial as part of a post completion analysis, we would write it off entirely. However, this was a prespecified subgroup and – while the drug didn’t work across the entire population – the company was able to show that it might work in a certain group of patients and, for us, that’s enough to warrant some degree of optimism, especially at current bargain bin prices.
Of course, if the company is going to recover any of the lost strength, it’s going to need a catalyst, so where is that coming from?
Well, this trial was in the US but there is also a very similar trial currently underway in Europe. The trial in question, called SCLERADEC-II, is a 40 patient study looking at the same patient population. if the data shows that the drug works in the diffuse subset of the population in this trial, or in other words, if it supports the efficacy readout in this population that we just got from the US study, there’s a good chance we will see this company start to pick up some of its lost strength.
Sure, markets are disappointed with Cytori’s seeming failure to target the entire scleroderma population, but if it can target a subsection, then there is still a fair amount of value in its primary asset. An estimated 300,000 Americans have scleroderma, about one-third of whom have the systemic form of the disease, known as systemic sclerosis (SSc). SSc is further broken into the two above noted categories – diffuse cutaneous and limited cutaneous SSc. Diffuse scleroderma (what we’re interested in here) accounts for between one-third and one-half of all cases of systemic sclerosis. Using these numbers, there are around 30,000-50,000 US patients that this drug seems to work for and approximately twice that in Europe.
To answer the question, then, yes, there’s still plenty to be optimistic about for Cytori and we’re looking to the outcome of SCLERADEC-II as a potential gap-closing catalyst as and when it hits press.
https://insiderfinancial.com/heres-why-you-shouldnt-write-of…
Cytori Therapeutics Inc (NASDAQ:CYTX) Could Still Win In Scleroderma. Here's How.
By Chris Sandburg
Posted on July 25, 2017
If you are looking for one of the biggest biotechnology losses of the week so far, look no further than Cytori Therapeutics Inc (NASDAQ:CYTX). The company closed out last week at around $1.10 a share. By market open on Monday, Cytori went for around $0.40 apiece and remained pretty much flat on the open to close out the session at $0.48 a share.
The decline comes on the back of the company putting out data from one of its lead investigations and – as readers might have guessed – the data not hitting press as Cytori or its shareholders might have hoped it would.
Markets are asking the question – is there any value in picking up exposure at current prices or is this an asset (and in turn, a company) to write off for now?
Here is our answer to that question.
The trial was rooted in a drug called Habeo that attempts to use what are called dipose-derived regenerative cells (ADRCs), which are living cells that are present in an adult human’s own adipose tissue, to help regenerate healthy tissue in conditions associated with cell degeneration. The company removes these cells from the patient using liposuction, adds them to a liquid suspension and then concentrates them into a substance that can be reintroduced into the body by way of subcutaneous injection.
In this instance, the target indication was scleroderma, which is a rare and chronic connective tissue disease generally classified as an autoimmune rheumatic disorder. It’s characterized by significant hand dysfunction, and this latter characterization played a key role in the trials determinant outcome.
So, specifically, the company injected its Habeo therapy into a total of 88 patients with scleroderma, including 51 patients with a type called diffuse cutaneous and 37 with another type called limited cutaneous scleroderma. These patients were then followed up at 24 and 48 weeks’ post-treatment to see if their scleroderma had improved, using a scale called the Cochin Hand Function Score (CHF score) to judge improvement.
As per the latest data, the drug failed against its primary endpoint (an improvement from baseline based on the above-mentioned CHF score) at both 24 weeks and 48 weeks.
So, not great.
It’s not all bad, however. The company did manage to show some degree of improvement (a statistically significant one at that) in one of the subgroups of patients – the patients with the diffuse cutaneous form of the disease.
This part is important: if this improvement was recognized after the trial as part of a post completion analysis, we would write it off entirely. However, this was a prespecified subgroup and – while the drug didn’t work across the entire population – the company was able to show that it might work in a certain group of patients and, for us, that’s enough to warrant some degree of optimism, especially at current bargain bin prices.
Of course, if the company is going to recover any of the lost strength, it’s going to need a catalyst, so where is that coming from?
Well, this trial was in the US but there is also a very similar trial currently underway in Europe. The trial in question, called SCLERADEC-II, is a 40 patient study looking at the same patient population. if the data shows that the drug works in the diffuse subset of the population in this trial, or in other words, if it supports the efficacy readout in this population that we just got from the US study, there’s a good chance we will see this company start to pick up some of its lost strength.
Sure, markets are disappointed with Cytori’s seeming failure to target the entire scleroderma population, but if it can target a subsection, then there is still a fair amount of value in its primary asset. An estimated 300,000 Americans have scleroderma, about one-third of whom have the systemic form of the disease, known as systemic sclerosis (SSc). SSc is further broken into the two above noted categories – diffuse cutaneous and limited cutaneous SSc. Diffuse scleroderma (what we’re interested in here) accounts for between one-third and one-half of all cases of systemic sclerosis. Using these numbers, there are around 30,000-50,000 US patients that this drug seems to work for and approximately twice that in Europe.
To answer the question, then, yes, there’s still plenty to be optimistic about for Cytori and we’re looking to the outcome of SCLERADEC-II as a potential gap-closing catalyst as and when it hits press.
https://insiderfinancial.com/heres-why-you-shouldnt-write-of…
Antwort auf Beitrag Nr.: 55.528.629 von Shanghai2006 am 15.08.17 15:25:51Das ist keine "normale KE", sondern eine Absprache zwischen "dem Unternehmen", den Hedgefonds und "weiteren Insidern" inkl. der SEC (Daher auch keine "Daten gefüllt" im SEC Filling)
Hier wird die komplette Marktkap. innerhalb eines Jahres mit Warrents verdoppelt (wie auch vorher wobei die Geschwidigkeit unfassbar ist).
Es gibt zwei Strategien - entweder die Jungs machen so weiter bis einer alle Aktien hat oder es wird so vor die Wand gefahren und einer übernimmt die Anteile.. Vorher wird mit Shorts Geld gemacht und Aktien gezielt verkauft
(Es ist auch kein Zufall das 11 Mill. Aktien nach einem Absturz von 60% kommen. Vorher hatte man auch bei 2$ absichtlich eine Meldung rausgebracht um eine KE zu 1$ durchführen zu können - am selben Tag
) - alles beleg- bzw. beweisbar..
So oder so - Die Absprache war hier schon lange und das illegale Handeln wird geduldet. da es von den Caymans gesteuert wird...
Ziel ist hier nicht Geld zur Finazierung der Firma zu bekommen, sondern die Anteile zu verteilen...
Hier wird die komplette Marktkap. innerhalb eines Jahres mit Warrents verdoppelt (wie auch vorher wobei die Geschwidigkeit unfassbar ist).
Es gibt zwei Strategien - entweder die Jungs machen so weiter bis einer alle Aktien hat oder es wird so vor die Wand gefahren und einer übernimmt die Anteile.. Vorher wird mit Shorts Geld gemacht und Aktien gezielt verkauft
(Es ist auch kein Zufall das 11 Mill. Aktien nach einem Absturz von 60% kommen. Vorher hatte man auch bei 2$ absichtlich eine Meldung rausgebracht um eine KE zu 1$ durchführen zu können - am selben Tag
) - alles beleg- bzw. beweisbar.. So oder so - Die Absprache war hier schon lange und das illegale Handeln wird geduldet. da es von den Caymans gesteuert wird...
Ziel ist hier nicht Geld zur Finazierung der Firma zu bekommen, sondern die Anteile zu verteilen...
Trading Spotlight
Antwort auf Beitrag Nr.: 55.428.213 von boyoboy am 31.07.17 17:51:36Mir geht es hier in erster Linie darum das die Manipulatoren nicht in den Knast wandern.
Bspw. : https://www.thestreet.com/story/14249680/1/pharma-bro-martin… martin-shkreli hat selbst HIER manipuliert. Dazu sieht man es seit Jahren wie es passiert.
"Das Management" gibt zus. Falsche Infos raus und manipuliert Ergebnisse von Studien oder veröffentlicht diese erst Monate später (s. vor 2 Jahren). Dazu werden gezielte Infos mit den HF abgesprochen und der Kurs eingestampft, damit man sich dann die ganzen Patente usw. für weniger als n paar Dollar kaufen kann und dann ein neues Unternehmen aufmacht und die Nummer wieder durchzieht.
All das unter den Augen der SEC - was eigentlich das schlimmste ist aber zeigt das man besser in die staatlich überwachten Spielcasinos geht, da hier wenigstens eine Überwachung stattfindet..
Was hier über JAHRE abgezogen wurde ließe sich mit den An und Verkäufen plus Depotinhaber locker auswerte, wenn jmd Interesse daran hätte
Bspw. : https://www.thestreet.com/story/14249680/1/pharma-bro-martin… martin-shkreli hat selbst HIER manipuliert. Dazu sieht man es seit Jahren wie es passiert.
"Das Management" gibt zus. Falsche Infos raus und manipuliert Ergebnisse von Studien oder veröffentlicht diese erst Monate später (s. vor 2 Jahren). Dazu werden gezielte Infos mit den HF abgesprochen und der Kurs eingestampft, damit man sich dann die ganzen Patente usw. für weniger als n paar Dollar kaufen kann und dann ein neues Unternehmen aufmacht und die Nummer wieder durchzieht.
All das unter den Augen der SEC - was eigentlich das schlimmste ist aber zeigt das man besser in die staatlich überwachten Spielcasinos geht, da hier wenigstens eine Überwachung stattfindet..
Was hier über JAHRE abgezogen wurde ließe sich mit den An und Verkäufen plus Depotinhaber locker auswerte, wenn jmd Interesse daran hätte
Antwort auf Beitrag Nr.: 55.427.826 von Merton75 am 31.07.17 17:07:54Deine Idee klingt gut, denn da stinkt vieles in diesem Laden. Meine Erfahrung ist, dass es nichts oder nur Brosamen bringt. Ich war an dem Wordcom Class Act beteiligt, von meinen Verlusten auf 2 Depots bekam ich etwa 1 Prozent zurück, verteilt über circa 10 bis 15 Scheck. Jeder Scheck kostete damals soweit ich weiß 15 Dollar Einlösegebühr. Zieht man die Scheckgebühren, Porti (per Einschreiben) und nicht zu vergessen die Arbeit ab, hat man draufgelegt.
Auch bei TFG/Vestcorp, Comroad und anderen meiner Depotleichen war kein Schadenersatz zu sehen.
Auch bei TFG/Vestcorp, Comroad und anderen meiner Depotleichen war kein Schadenersatz zu sehen.
Antwort auf Beitrag Nr.: 55.413.272 von boyoboy am 28.07.17 15:35:44Sollte sich ja rausfinden lassen wem die Seit(en) gehören und wer gepusht hat.
Zudem ist die Akquisition in 2017 in Kombination zu einer KE zu 1$ (bei einem Kurs von 2$) mehr als "dubios" bei gleichzeitigen Schulden inkl. einer Marketcap. von nun 15m$.. Bei einem Chapter 11 wird man sehen an wen das alles geht und ob der "Investor" an allem beteiligt war. (gibt jeden Jahr zig Bspw. und über Konten ließe sich das nachweisen, wenn man wollen würde)
Alles in allem ein Beweis das dies mehr ist als Roulette, da es hierbei wenigstens eine Überwachung gibt und man von einem legalen Spiel ausgehen kann...
Zudem ist die Akquisition in 2017 in Kombination zu einer KE zu 1$ (bei einem Kurs von 2$) mehr als "dubios" bei gleichzeitigen Schulden inkl. einer Marketcap. von nun 15m$.. Bei einem Chapter 11 wird man sehen an wen das alles geht und ob der "Investor" an allem beteiligt war. (gibt jeden Jahr zig Bspw. und über Konten ließe sich das nachweisen, wenn man wollen würde)
Alles in allem ein Beweis das dies mehr ist als Roulette, da es hierbei wenigstens eine Überwachung gibt und man von einem legalen Spiel ausgehen kann...
Antwort auf Beitrag Nr.: 55.393.139 von Turnover15 am 26.07.17 08:46:22
Quelle: http://www.cytori.com/about/
Und die Cytori Fanseite ist auch schon tot.
http://www.junge-füchse.de/adhocs.htm
Wie sagte einst Kostolany:
"Ein Mann kann zwischen mehreren Methoden wählen, sein Vermögen loszuwerden: Am schnellsten geht es am Roulette-Tisch, am angenehmsten mit schönen Frauen und am dümmsten an der Börse."
"A History of Excellence"
"A History of Excellence"Quelle: http://www.cytori.com/about/
Und die Cytori Fanseite ist auch schon tot.
http://www.junge-füchse.de/adhocs.htm
Wie sagte einst Kostolany:
"Ein Mann kann zwischen mehreren Methoden wählen, sein Vermögen loszuwerden: Am schnellsten geht es am Roulette-Tisch, am angenehmsten mit schönen Frauen und am dümmsten an der Börse."
Durchsuchen
